ABVC BioPharma (ABVC) Stock Price, News & Analysis

Company Overview

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders and certain cancers. The company’s approach combines internally developed drug candidates with technologies licensed from academic and research institutions.

Its development programs have included candidates for major depressive disorder, attention-deficit/hyperactivity disorder and other neurological conditions, as well as investigational treatments in oncology. ABVC has also pursued companion diagnostic and biomarker-related technologies intended to support drug development and patient selection.

Headquartered in Fremont, California, ABVC BioPharma has worked with research and clinical partners in the United States and internationally, including institutions in Taiwan. The company was formerly known as American BriVision (Holding) Corp. and changed its name to ABVC BioPharma, Inc. as it expanded its focus on biotechnology development programs.

Key Stats

• Today's Range: $1.11 to $1.21
• 50-Day Range: $0.71 to $1.35
• 52-Week Range: $0.71 to $3.40
• Volume: 199,552 shs
• Average Volume: 121,097 shs
• Market Capitalization: $30.91 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

ABVC BioPharma Stock Analysis - MarketRank™

ABVC BioPharma scored higher than 2% of companies evaluated by MarketBeat, and ranked 889th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

ABVC BioPharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

ABVC BioPharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of ABVC BioPharma is -3.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ABVC BioPharma is -3.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ABVC BioPharma has a P/B Ratio of 2.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.43% of the float of ABVC BioPharma has been sold short.

Short Interest Ratio / Days to Cover

ABVC BioPharma has a short interest ratio ("days to cover") of 5.45.

Change versus previous month

Short interest in ABVC BioPharma has recently increased by 22.26%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ABVC BioPharma does not currently pay a dividend.

Dividend Growth

ABVC BioPharma does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added ABVC BioPharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ABVC BioPharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.00% of the stock of ABVC BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

11.38% of the stock of ABVC BioPharma is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 9/19/2026
• Next Earnings (Estimated): 11/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ABVC
• CIK: 1173313
• Web: www.abvcpharma.com
• Phone: (510)-668-0881
• Fax: N/A
• Employees: 19
• Year Founded: 2002

Profitability

• EPS (Trailing Twelve Months): ($0.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.91 million
• Net Margins: N/A
• Pretax Margin: -954.77%
• Return on Equity: -47.68%
• Return on Assets: -30.97%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.07
• Quick Ratio: 0.07

Sales & Book Value

• Annual Sales: $510 thousand
• Price / Sales: 60.62
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.52 per share
• Price / Book: 2.23

Miscellaneous

• Outstanding Shares: 26,650,000
• Free Float: 21,590,000
• Market Cap: $30.91 million
• Optionable: Not Optionable
• Beta: 0.61